绝经激素治疗与乳腺癌风险综述
绝经激素治疗(MHT)是缓解更年期症状最有效的方法,但乳腺癌风险是共同决策的核心关切。MHT相关乳腺癌风险因个体基线风险和方案类型而异;子宫切除术后单用雌激素风险低于雌孕激素联合方案,微粒化黄体酮和地屈孕酮在观察性研究中似乎风险低于其他孕激素,但尚无随机研究验证。处方MHT前应评估乳腺癌基线风险并教育可改变的风险因素。
要点
- 子宫切除术后单用雌激素的乳腺癌风险低于雌孕激素联合方案。
- 微粒化黄体酮和地屈孕酮的乳腺癌风险在观察性研究中低于其他孕激素。
- 处方MHT前应评估乳腺癌基线风险并教育可改变的风险因素。
核心结论
- MHT相关乳腺癌风险因个体基线风险和方案类型而异,处方前应评估基线风险并教育可改变风险因素。
研究设计与样本
- 综述整合当代随机和观察性证据,涵盖药理学差异、与可改变风险因素的交互及共同决策启示。
主要发现
- 子宫切除术后单用雌激素的乳腺癌风险似乎低于雌孕激素联合MHT。
- 观察性或病例对照研究显示微粒化黄体酮和地屈孕酮的乳腺癌风险低于孕激素,但无随机研究验证。
临床怎么用
- 处方MHT前应将评估乳腺癌基线风险作为最低标准,并教育可改变的风险因素。
- 共同决策时应结合个体基线风险和MHT方案类型讨论乳腺癌风险。
局限性
- 微粒化黄体酮和地屈孕酮风险低于孕激素的证据仅来自观察性或病例对照研究,无随机研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer risk is a central concern in shared decision-making when considering menopausal hormone treatment (MHT). Women spend approximately 40% of their lives in menopause, and climacteric symptoms can substantially impair quality of life. MHT is the most effective strategy to treat climacteric symptoms. MHT can consist of the administration of oestrogen only in women who have undergone hysterectomy or a combined treatment of oestrogen and progestogen in women with a uterus. The risk of breast cancer associated with MHT varies with both the individual's baseline risk of breast cancer and the type of treatment. Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer than combined oestrogen and progestogen MHT. Micronised progesterone and dydrogesterone seem associated with a lower risk of breast cancer than progestins, as shown in observational or case-control studies, but no randomised study has addressed this questions. Evaluating baseline risk of breast cancer before prescription of MHT should be considered a minimum standard alongside education on risk factors that can help decrease the risk of breast cancer with or without using MHT. This Review synthesises contemporary randomised and observational evidence, including pharmacologic distinctions, interaction with modifiable risk factors, and implications for better shared decision-making for women considering MHT.
引用
- Gompel A, Simcock R. Menopausal hormone treatment and breast cancer. Lancet Diabetes Endocrinol. 2026. PMID: 41619758. doi:10.1016/S2213-8587(25)00394-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。